Table 3 Factors associated with relapse: comparison of patients with and without relapses

Male sex, n (%)

23 (29.1)

21 (39.6)

0.286

Age, years, median [IQR]

53.50 [38.75, 66.25]

60.50 [40.75, 69.25]

0.343

 Thrombotic phenotype (pure), n (%)

61 (77.2)

33 (62.3)

0.096

 Obstetrical phenotype (pure), n (%)

14 (17.7)

4 (7.5)

0.158

 Combined APS, n (%)

4 (5.1)

17 (32.1)

<0.001

 Number of thrombosis, n (%)

<0.001

  None

15 (19.0)

6 (11.3)

  One

53 (67.1)

22 (41.5)

  Two or more

11 (13.9)

25 (47.2)

 Arterial thrombosis, n (%)

28 (35.4)

23 (43.4)

0.461

 Venous thrombosis, n (%)

40 (50.6)

32 (60.4)

0.356

 Miscarriages, n (%)

10 (13.2)

6 (11.8)

1.000

 Intrauterine deaths, n (%)

5 (6.6)

5 (9.8)

0.745

 Prematurity, n (%)

4 (5.3)

4 (7.8)

0.830

 IUGR, n (%)

1 (1.3)

3 (5.9)

0.362

 Pre-eclampsia, HELLP syndrome, n (%)

2 (2.6)

7 (13.7)

0.042

 CAPS, n (%)

0 (0.0)

2 (3.8)

0.304

 Arterial hypertension, n (%)

23 (39.0)

13 (41.9)

0.964

 Dyslipidemia, n (%)

11 (18.6)

8 (25.8)

0.603

 Tobacco, n (%) = 1 (%)

9 (17.0)

7 (35.0)

0.179

 Diabetes mellitus, n (%)

9 (15.8)

3 (15.0)

1.000

 Overweight, n (%)

7 (15.9)

9 (32.1)

0.185

 Non-criteria features, n (%)

14 (17.7)

20 (37.7)

0.018

 Number of non-criteria features, median [IQR]

0.00 [0.00, 0.00]

0.00 [0.00, 1.00]

0.007

 Triple positivity, n (%)

17 (23.0)

18 (36.7)

0.147

 Antinuclear antibodies, n (%)

11 (19.6)

11 (29.7)

0.384

 Vitamin K antagonists, n (%)

39 (52.7)

45 (90.0)

<0.001

 Antiplatelet therapy, n (%)

30 (39.0)

26 (53.1)

0.171

 Hydroxychloroquine, n (%)

6 (7.8)

16 (32.7)

0.001

 Steroids, n (%)

10 (13.0)

14 (29.8)

0.039

 Death, n (%)

5 (13.5)

5 (4.9)

0.167

 Follow-up, years, median [IQR]

5.37 [0.96, 11.98]

2.95 [1.09, 7.83]

0.191